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Optical imaging-based methods for assessing the membrane electrophysiology of in vitro human cardiac
cells allow for non-invasive temporal assessment of the effect of drugs and other stimuli. Automated
methods for detecting and analyzing the depolarization events (DEs) in image-based data allow quan-
titative assessment of these different treatments. In this study, we use 2-photon microscopy of ﬂuor-
escent voltage-sensitive dyes (VSDs) to capture the membrane voltage of actively beating human in-
duced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs). We built a custom and freely available
Matlab software, called MaDEC, to detect, quantify, and compare DEs of hiPS-CMs treated with the β-
adrenergic drugs, propranolol and isoproterenol. The efﬁcacy of our software is quantiﬁed by comparing
detection results against manual DE detection by expert analysts, and comparing DE analysis results to
known drug-induced electrophysiological effects. The software accurately detected DEs with true posi-
tive rates of 98–100% and false positive rates of 1–2%, at signal-to-noise ratios (SNRs) of 5 and above. The
MaDEC software was also able to distinguish control DEs from drug-treated DEs both immediately as
well as 10 min after drug administration.1. Introduction
The derivation of human induced pluripotent stem cells (hiPSs)
from somatic human cells has opened broad opportunities in the
study of human cardiac cells. Previously limited by their minimal
proliferation, human cardiomyocytes were difﬁcult to obtain in
signiﬁcant number to allow widespread study. hiPS cells can be
expanded into the required quantities and then differentiated into
cardiomyocytes (hiPS-CMs) as a new, and seemingly endless, source
of cardiomyocytes [18,30]. Accompanying this expanded availability,
there has been an acceleration of the development of new methods
for assessing the electrophysiological effects of drug compounds.
Image-based tools for assessing excitable cells, such as cardiomyo-
cytes, have particularly come to the fore [3,5,14,22,25,27]. With
these new data acquisition methods comes a need for automated,
user friendly, analysis methods of these image-based data.
Voltage-sensitive dyes (VSDs) are one such method for ac-
quiring membrane voltage data. These dyes associate with cellular
membranes and exhibit a characteristic increase in ﬂuorescence
intensity proportional to an increase in voltage across theSzymanska).membrane. This allows for non-invasive, non-destructive, and
longitudinal assessment of hiPS-CM electrophysiology [11,29].
VSDs have previously been used in neuronal [8,21] and cardiac
[7,10,15] cells and tissues. A wide range of VSD compounds and
properties have been synthesized [29]. This study utilizes di-4-
ANE(F)PPTEA, a hemicyanine class dye, to acquire a temporal
ﬂuorescent signal that corresponds to the changing voltage of
hiPS-CM membranes.
To quantitatively assess these data acquired using VSDs in hiPS-
CM, we built a custom Matlab software (MaDEC), capable of both
detecting and analyzing individual VSD depolarization waveforms
or depolarization events (DEs). Our previous work has analyzed
hiPS-CM electrophysiology by performing supervised machine
learning on pre-deﬁned DE parameters [11] of already detected
DEs. Here, detection is performed using a generalized matched
ﬁlter for the entire waveform instead. This allows for non-biased
event selection, as well as more reliable event selection in low-
SNR environments. This detection method was previously shown
to be successful for neuronal action potential detection in extra-
cellularly recorded micro-electrode data [23], as well as neuronal
calcium transient wave detection in calcium imaging data [24].
The detected DEs are subsequently compared, using a KS-test,
across treatments and time points. The chronotropic drugs pro-
pranolol and isoproterenol were selected to validate this VSD-
based approach and the corresponding analysis software. This
method of analysis allows for quantitative assessment of the het-
erogeneity of DEs at a precise location on the membrane of an
actively beating cardiomyocyte. Furthermore, this method allows
quantitative assessment of how a given drug affects the DE shape
of an actively beating cardiomyocyte.
In this study, we use 2-photon microscopy of ﬂuorescent VSD
to assess the depolarization of the cell membrane voltage of ac-
tively beating hiPS-CMs. Using MaDEC, we detect, quantify, and
compare DEs of hiPS-CMs treated with common β-adrenergic
drugs. The efﬁcacy of our software is quantiﬁed by comparing
detection results against manual DE detection by expert analysts,
and comparing DE analysis results to known drug induced elec-
trophysiological effects.2. Methods
2.1. Human induced pluripotent stem cell-derived cardiomyocyte
(hiPS-CM) culture and differentiation
hiPS-CMs were prepared for interrogation per the protocol
previously described by Heylman et al. [11]. Brieﬂy, wtc11 hiPS
cells were differentiated into cardiomyocytes using a serum-free
deﬁned medium protocol [16]. Cells began spontaneously beating
on approximately Days 12–15, and were stained with VSD and
imaged on Day 33.
2.2. Voltage-sensitive dye staining and drug exposure
Culture medium was replaced with fresh medium containing
1 μM di-4-ANE(F)PPTEA (purchased from Leslie Loew, University
of Connecticut) and incubated for 15 min at 37 °C. Cells were
rinsed with RPMI/B-27 (þ) insulin one time and then allowed to
recover for at least 2 h prior to imaging. After staining with VSD,
cells were qualitatively conﬁrmed to still be spontaneously beating
before addition of drugs. Medium was then replaced with fresh
medium containing either μ−10 M5 propranolol (SIGMA, P0884) or
μ−10 M7 isoproterenol (SIGMA, I6504). Data was collected im-
mediately after addition of drugs (less than 60 s of exposure) and
again 10 min or 15 min after addition to ensure complete ex-
posure. Control images were captured from VSD stained cultures,
not treated with either drug.
2.3. Two-photon microscopy
A Zeiss LSM 710 microscope (Carl Zeiss, Jena, Germany) with a
40X water immersion objective (C-Apochromat 40X/1.20 W Korr
M27) was used for all measurements. VSD was excited by 850 nm
light produced by a titanium:sapphire Mai Tai laser (Spectra-
Physics, Mountain View, CA). Excitation light was separated from
emission signal with a 760 nm dichroic. VSD ﬂuorescence was
collected in the 489–645 nm range. Line scan mode with 128
pixels per line and a 1.58 μs pixel dwell time was used to acquire
temporal VSD depolarization data. Given a 1.67 kHz sampling rate,
the total scan time per line was 600 μs. Each measurement con-
sisted of 100,000 line scan repeats (total scan time 60 s). The Zen
software package (Zeiss, Jena, Germany) was used to control all
microscope components and acquisition processes. Brightﬁeld
images were used to identify clusters of spontaneously beating
cardiomyocytes. The system was then switched to line scan mode
with the parameters speciﬁed above. Line scan data were acquired
along a line that was manually drawn across cell membranes. After
completion of data acquisition, the system was switched back to
brightﬁeld mode to conﬁrm that the cells were still spontaneously
beating.2.4. Data pre-processing
SimFCS commercial software developed in the Laboratory of
Fluorescence Dynamics (LFD, University of California, Irvine) was
used to analyze raw ﬂuorescence data. A Gaussian tracking and
correction algorithm (Supplemental Fig. 6) was used to compen-
sate for motion artifacts resulting from the spontaneous beating of
cell clusters. Fluorescence intensity along each corrected cell
membrane trace was then extracted. Finally, a custom Matlab
script that ﬁt and subtracted a biexponential function from the
resultant data was used to remove photobleaching artifacts (Sup-
plemental Fig. 7).
2.5. Manual identiﬁcation of depolarization events
Intensity traces, X, for all drug and control conditions, as de-
scribed in Section 2.2, were derived as described in Section 2.4,
and plotted in Matlab. Three trained human analysts then in-
dependently identiﬁed DE peak times from each trace.
2.6. DE detection and comparison analysis (MaDEC)
We have designed a custom Matlab software package to detect,
quantify, and compare DEs of hiPS-CMs treated with common β-
adrenergic drugs. The package consists of two components. First,
the DEs are detected using a Matched-ﬁlter for Depolarization
event (MaD) detection. The detected DEs are then quantitatively
compared using our DE Comparison tool (DEC). Combined, these
two tools are referred to as MaDEC. MaDEC was implemented in
Matlab and is freely available along with a graphical user interface
at sites.uci.edu/aggies/downloads or from the corresponding
author.
2.6.1. Matched-ﬁlter for Depolarization event detection (MaD)
The matched ﬁlter used here was ﬁrst implemented in Szy-
manska et al. [24]. A few modiﬁcations were made to tailor the
ﬁlter speciﬁcally to voltage-sensitive dye and cardiomyocyte data,
resulting in the MaD detector. Brieﬂy, given a ﬂuorescence in-
tensity signal ∈ ×x N1 , where N is the number of samples span-
ning a DE, and assuming Gaussian noise statistics, we can express
a decision rule as
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is the test statistic and matched-ﬁlter output, ∈ ×s N1 is the DE
template, Σ ∈ ×N N is the noise covariance matrix, γ is the
threshold, H0 is the null hypothesis (the signal contains noise
only), and H1 is the alternative hypothesis (the signal contains
both noise and a DE). To detect DEs in the entire line scan, the
matched ﬁlter is convolved with the full line scan signal ∈ ×X T1 ,
where ⪢T N , and DEs are identiﬁed as peaks of activity above the
threshold, γ.
MaD detector training protocol. The MaD detector is completely
data driven as both s and Σ from Eq. (1) are estimated from the
data. This allows the detector to be very ﬂexible in accommodating
various DE sizes, shapes, and durations, depending on the drug
treatment applied and the speciﬁc data collected. The detector was
trained under three detection conditions. The ﬁrst was no drug
exposure (control); the second was isoproterenol exposure and
included data immediately after and 10 min after addition of iso-
proterenol; the third was propranolol exposure and included data
immediately after and 10 min after addition of propranolol. The
appropriately trained detector was then used to extract DEs from
the data.
Table 1
Training sample information for each drug treatment. Average training DE SNR is
the average SNR of the 20 DEs selected for training for a given drug treatment. The
number of windows the training noise sample for each data set could be split into
is also listed.
Training condition Average training DE
SNR
Number of training noise
windows
Control 5.70 34
Isoproterenol 148.07 17
Propranolol 158.97 37In order to estimate s and Σ, 20 high-SNR DEs
( = ≃ )N 800 0.48 s , as well as 20 noise-only data samples, were
identiﬁed manually for each detection condition. Analysts identi-
ﬁed between 81 and 142 DEs in the control data, depending on the
analyst (Table 2). Therefore, the 20 control training DEs represent
14–25% of the total control DEs. Similarly, the 20 isoproterenol
training DEs represent 15–16% of the total isoproterenol DEs, and
the 20 propranolol training DEs represent 24% of the total pro-
pranolol DEs. These training DEs were then aligned to their peak
values, and averaged to construct s for each detection condition.
The identiﬁed training noise samples were subdivided into win-
dows ( = ≃ )N 800 0.48 s , and auto-covariance sequences, r(k), were
then calculated at lags ∈ { − − … }k 399, 398, , 399 for each noise
window. The total available noise in each detection condition is
difﬁcult to quantify, however we can present the training noise for
each detection condition in terms of a percentage of the full data
for that detection condition. The training noise samples in the
control condition, isoproterenol condition, and propranolol con-
dition represent 14%, 7%, and 15% of the control, isoproterenol, and
propranolol data, respectively. The Σ for each detection condition
was generated by averaging the auto-covariance sequences across
that detection condition's noise windows.
The size of s and each noise window was empirically selected
as = ≃N 800 0.48 s to ensure that most DEs were captured in full,
although some data sets did exhibit both wider and slimmer DEs
depending on the drug treatment. The number of noise windows
for a given drug treatment varied depending on the length of
available noise-only segments in the pre-processed data. Likewise,
the shape and SNR of DEs used for estimating s varied between
drug treatments. Examples of s from both propranolol and iso-
proterenol drug treatments, as well as the control, are shown in
Fig. 1. The average SNR of the training DEs, as well as the number
of training noise windows available for each drug treatment is
listed in Table 1.
2.6.2. DE comparison (DEC) analysis
Once the DEs were detected from each data trace, the in-
dividual spikes were extracted from the data and normalized such
that the average DE for any given data trace had a minimum value
of 0 and a maximum value of 1. This approach allowed us to
preserve within data trace variations around the average DE, while
also normalizing DE amplitudes across different data traces. We
chose to normalize the DEs because their amplitudes are highly
dependent on photobleaching, exact position in the imaging plane,
as well as howmuch of the VSD each membrane initially absorbed.
It is therefore unreliable to compare DE amplitudes across treat-
ments and time. Each DE was deﬁned by a window consisting ofFig. 1. Examples of training templates s from control (left), isoproterenol (middle),
and propranolol (right) data. Each template is 0.48 s long.800 time points ( ≃ )0.48 s centered on the maximum value of the
DE. The average waveforms were calculated for each data trace.
The full-width half-max (width), the positive slope at half-max
(upslope), and the negative slope at half-max (downslope) were
calculated for each identiﬁed DE. These parameters were com-
pared as a function of drug treatment and time elapsed after drug
treatment using a two-sample Kolmogorov–Smirnov (KS) test at a
5% signiﬁcance level.3. Results
A total of 7 data traces, from 5 cell cultures, were tested. The
ﬁrst 5 conditions are a control (cell culture 1), immediately after
addition of isoproterenol (cell culture 2), 10 min after addition of
isoproterenol (cell culture 2), immediately after addition of pro-
pranolol (cell culture 3), and 10 min after addition of propranolol
(cell culture 3). These conditions will now be referred to as Con-
trol-1, Iso-1 0 min, Iso-1 10 min, Pro-1 0 min, and Pro-1 10 min,
respectively. In order to better test MaDEC in low-SNR environ-
ments we also provide results for a low-SNR control data case (cell
culture 4), as well as a low-SNR 15 min after addition of iso-
proterenol case (cell culture 5). These two conditions will now be
referred to as Control-2 and Iso-2 15 min, respectively.
3.1. Detection
3.1.1. Manual depolarization event identiﬁcation
Three trained analysts identiﬁed DE peak times in all 7 pre-
sented data traces. The number of identiﬁed DEs as well as the
average DE SNR for each analyst and each data trace is shown in
Table 2. The SNR of a given DE was calculated as
σ= ( )E DESNR /DE noise2 2 , where E is the expectation operator and σnoise2
was calculated from the 20 noise samples manually selected from
each given data trace. Each analyst's percentage of agreement with
unanimously identiﬁed DEs is also presented as a global measure
of analyst consistency.
The average SNR of the DEs identiﬁed in the Control-1 trace
was 5.67. The unanimously identiﬁed Control-1 DEs had a slightly
higher SNR of 5.71. The average analyst agreement with unan-
imous Control-1 DEs was 98.87% (only 1 DE was not unanimous).
The average SNRs for the Iso-1 and Pro-1 data sets were an order
of magnitude higher than the Control-1 DEs. Iso-1 DEs identiﬁed
by analysts had an average SNR of 69.74, and unanimous Iso-1 DEs
had a slightly higher SNR of 70.58. Here the average analyst
agreement was 99.03% (only 2 DEs were not unanimous). Analysts
were unanimous about 100% of the Pro-1 DEs and the average Pro-
1 DE SNR was 30.97. Examples of the DEs identiﬁed by the analysts
in each of these drug treatments are shown in Fig. 2
The average SNR of the DEs identiﬁed in the Control-2 trace was
3.07. The unanimously identiﬁed Control-2 DEs had a slightly higher
SNR of 3.19. Given this relatively low SNR, the average analyst agree-
ment with unanimous Control-2 DEs was only 75.52%. The average
SNR of the Iso-2 15 min trace was even lower, at 0.63. Unanimously
Table 2
Number and average SNRs of manually identiﬁed DEs for each analyst and each data trace. The last column shows the number and average SNR of DEs unanimous among
all 3 analysts. The percentage agreement between each analyst and the unanimous DEs is also shown.
Treatment Analyst Unanimous DEs
1 2 3 Average
Control-1 # DEs 60 59 60 59.67 59
Avg. SNR 5.64 5.71 5.64 5.67 5.71
Agreement (%) 98.31 100 98.31 98.87
Control-2 # DEs 81 142 94 105.67 76
Avg. SNR 3.12 2.91 3.18 3.07 3.19
Agreement (%) 92.18 53.52 80.85 75.52
Iso-1 0 min (# DEs) 63 63 62 62.75 62
10 min (# DEs) 66 67 67 66.50 66
Avg. SNR 69.76 69.32 70.15 69.74 70.58
Agreement (%) 99.22 98.46 99.22 99.03
Iso-2 15 min (# DEs) 43 107 46 65.33 38
Avg. SNR 0.70 0.58 0.61 0.63 0.65
Agreement (%) 88.37 35.51 82.61 68.83
Pro-1 0 min (# DEs) 55 55 55 55 55
10 min (# DEs) 29 29 29 29 29
Avg. SNR 30.97 30.97 30.97 30.97 30.97
Agreement (%) 100.00 100.00 100.00 100.00
Fig. 2. Detector performance. The ﬁgure consists of three pre-processed intensity traces from the Control-1 (top), Iso-1 (middle), and Pro-1 (bottom) drug treatments. The
circles above each data trace represent the DEs identiﬁed by analysts 1–3 (bottom to top, respectively). The triangles above each data trace represent MaD detected DEs, using
the optimal thresholds identiﬁed in the corresponding ROC curves to the right. The optimal threshold is identiﬁed as the one resulting in the detector performance closest to
TP¼100% and FP¼0%. The error bars represent 95% conﬁdence intervals. The optimal performance for each drug treatment case is presented under each ROC curve. The MaD
detector performed with a TP rate of 98–100% and a FP rate of 1–2% for all 3 drug treatments.identiﬁed Iso-2 15 min DEs had an SNR of 0.65. Similarly, the average
analyst agreement with unanimous Iso-2 15 min DEs was very low, at
only 68.83%. Examples of the DEs identiﬁed by the analysts in both of
these low-SNR conditions are shown in Fig. 3
3.1.2. MaD detector performance
A total of 5 detection cases were considered: Control-1, Iso-1, Pro-1,Control-2, and Iso-2, where the last 2 (Control-2 and Iso-2) represent
specially selected low-SNR data. Unanimous DEs between all 3 ana-
lysts were used as the ground-truth for assessing MaD performance. If
a detected DE was within 0.12 s, or one quarter of the length of a
typical DE, of the true peak time, it was considered a true positive (TP).
Otherwise, the detected DE was considered a false positive (FP). Ex-
amples of detected DEs are shown in Figs. 2 and 3.
Fig. 3. Detector performance at low SNR. The ﬁgure consists of two pre-processed intensity traces from the low SNR control, Control-2 (top), and the low SNR isoproterenol,
Iso-2 (bottom), drug treatments. The circles above each data trace represent the DEs identiﬁed by analysts 1–3 (bottom to top, respectively). The triangles above each data
trace represent MaD detected DEs, using the optimal thresholds identiﬁed in the corresponding ROC curves to the right. The error bars represent 95% conﬁdence intervals.
The optimal performance for each drug treatment case is presented under each ROC curve. As the SNR decreased, the performance of the MaD detector also decreased.
Performance was still adequate for ≃SNR 3, but not for ≤SNR 1.A true positive vector tp was used to represent all of the
ground-truth DEs in a given detection case. If a given DE was
successfully detected (TP) it was assigned a value of 1, and
0 otherwise. Similarly, a false positive vector fp was used to re-
present all of the detected DEs in a given detection case, with each
detected DE assigned a value of 1 if the DE was a FP, and 0 other-
wise. The means of tp and fp, representing TP and FP rates, re-
spectively, were then calculated at 45 incrementally increasing
thresholds for each detection case. The TP and FP rates at each
threshold were then used to generate receiver operating char-
acteristic (ROC) curves for each detection case (Figs. 2 and 3).
The threshold at which detector performance is closest to
TP¼100% and FP¼0% is the optimal threshold and constitutes the
best detector performance for that detection case. All following
performance metrics are presented as TP or FP Rate [95% con-
ﬁdence interval]. The best performance for the Control-1 case was
= [ ]TP 97.92 92.15, 100.00 % and = [ ]FP 1.75 0.00, 5.26 % at a
threshold of 4 standard deviations above the noise mean. The best
performance for the Iso-1 case was = [ ]TP 100.00 100.00, 100.00 %
and = [ ]FP 0.78 0.00, 2.33 % at a threshold of 8 standard deviations
above the noise mean, and the best performance for the Pro-1 case
was = [ ]TP 98.81 96.43, 100.00 % and = [ ]FP 1.19 0.00, 3.57 % at a
threshold of 6 standard deviations above the noise mean. Overall,
the MaD detector performed on par with human analysts and
accurately identiﬁed DEs at SNR levels of 5 and above.
Performance decreased in the low-SNR detection cases. The best
performance for the Control-2 case was = [ ]TP 72.37 61.84, 81.58 %
and = [ ]FP 16.67 7.58, 25.76 % at a threshold of 4 standard deviations
above the noise mean. The best performance for the Iso-2 case was
= [ ]TP 65.79 49.99, 81.59 % and = [ ]FP 13.79 0.44, 27.14 % at a
threshold of 2 standard deviations above the noise mean. Note that
the training used for detection in the Control-2 and Iso-2 cases was
derived from the Control-1 and Iso-1 data sets, respectively. The low
analyst agreement, ranging from 76% to 69%, in these low-SNR de-
tection cases made it very difﬁcult to reliably select training samples
from the Control-2 and Iso-2 data traces. Therefore, training from the
higher SNR data traces had to be used instead. If training data could be
reliably selected from the Control-2 and Iso-2 data traces, it is likely
that the lower quality of the training samples would adversely affect
detection performance.3.1.3. White Gaussian noise vs. fully colored noise
The full noise covariance extracted from the training data
(Section 2.6.1) is a very accurate estimate of the noise parameters.
However, if the training noise sample is too small the full noise
covariance could be poorly estimated and it may be advantageous
to make the simplifying assumption that the noise is temporally
white. The parameters, Σi j, , of the noise covariance matrix, Σ, are
zero if ≠i j, under the white Gaussian noise (WGN) assumption.
Furthermore, the diagonal parameters of Σ are all σ2. The covar-
iance matrix then takes on the form Σ σ= ×IN N2 , and the matched
ﬁlter output is then calculated as
σ
( ) = ( )S x s x
1
2
T
2
We have tested the effects of employing the WGN assumption
on the data presented in this paper. All subsequent results are
presented at best performance as (TP% / FP%). Although the WGN
assumption is a less accurate representation of the noise para-
meters than the full noise covariance, performance under the
WGN assumption was not signiﬁcantly affected in the Iso-1
(100.00%/0.78%) or Pro-1 (97.62%/2.38%) detection cases (ROC
curves not shown in the interest of space). The Control-1 case,
suffered slightly in performance (93.22%/5.17%), but is still within
the previously quoted conﬁdence interval. The Control-2 case
showed a more marked decrease in detection efﬁcacy (85.53%/
32.29%). Curiously, the Iso-2 case, which has the lowest SNR of all
of the data presented in this work, showed an increase in both the
best TP rate, and the best FP rate (89.47%/34.62%), which resulted
in a comparable overall performance.
These results imply that the matched ﬁlter under a WGN as-
sumption is sufﬁcient for DE detection at SNR levels of 5 and
higher, but may lead to a decrease in detection efﬁcacy at lower
SNRs.
3.2. DE analysis
The DEs detected at optimal thresholds as determined in Sec-
tion 3.1.2 were used for spike analysis. All p-values associated with
this analysis, as well as the average DEs of the treatments being
compared, are shown in Figs. 4 and 5. Two DE groups were con-
sidered distinguishable if at least one of the metrics being
Fig. 4. DE analysis with respect to drug treatment and time after drug administration. 6 panels are shown. Each panel shows the average DEs of the two speciﬁed drug
treatments, with standard deviations shaded around the average. The title of each panel identiﬁes the two treatments being compared. The text below the title indicates
whether the DE populations were different in width, upslope, and downslope, and provides p-values. The top 3 panels, going from left to right, compare Iso-1 0 min, (green)
to Control-1 (red), Iso-1 10 min (light teal) to Control-1, and Iso-1 0 min to Iso-1 10 min. Both Iso-1 0 min and Iso-1 10 min were different from Control-1, and were different
from each other, in all three parameters (width, upslope, and downslope). The bottom 3 panels, going from left to right, compare Pro-1 0 min (purple) to Control-1 (red), the
Pro-1 10 min (blue) to Control-1, and Pro-1 0 min to Pro-1 10 min. Both Pro-1 0 min and Pro-1 10 min were different from Control-1 in width, upslope, and downslope. They
were also different from each other in width and upslope. (For interpretation of the references to color in this ﬁgure caption, the reader is referred to the web version of this
paper.)measured (DE widths, upslopes and downslopes) were statistically
different between the two groups, as determined by KS-tests. The
drug treatments were ﬁrst compared with controls, and then
across time elapsed since drug administration.
The higher SNR drug treated data (Iso-1 and Pro-1) were
compared to the higher SNR control (Control-1). The Iso-1 0 min
drug treatment was statistically distinguishable from Control-1 in
width ( − = × )−p value 3.6 10 5 , upslope ( − = × )−p value 7.9 10 7 , and
downslope ( − = × )−p value 6.4 10 6 . This difference was maintained
10 min after isoproterenol was administered (Iso-1 10 min) (width
− = × −p value 5.0 10 8, upslope − =p value 0.02, downslope
− = × −p value 1.6 10 7). DEs measured immediately after propra-
nolol administration (Pro-1 0 min) were also already statistically
distinguishable from Control-1 in width ( − = × )−p value 7.0 10 11 ,
upslope ( − = × )−p value 2.5 10 3 , and downslope
( − = × )−p value 1.1 10 4 . This difference was also maintained 10 min
after propranolol was administered (Pro-1 10 min) (width
− = × −p value 1.5 10 7, upslope − = × −p value 1.1 10 8, downslope
− = × −p value 5.5 10 7). These results (shown in Fig. 4) indicate that
this analysis method can distinguish DEs from control and drug
treatments even less than a minute after the drug is administered(0 min cases). The distinctions are also maintained 10 min after
drug administration.
To show that the method is also applicable in a low-SNR set-
ting, we performed a DE comparison analysis on Control-2 (aver-
age =SNR 3.07) and Iso-2 15 min (average =SNR 0.63). The Iso-2
15 min drug treatment was statistically distinguishable from
Control-2 in width ( − = )p value 0.02 , but not in either upslope
( − = )p value 0.68 or downslope ( − = )p value 0.25 . These results are
shown in Fig. 5. We would expect the DE width difference to be
most pronounced among these two cases. This is reﬂected in the
results. As SNR is decreased the DE widths remain the only dis-
tinguishable parameters, while upslope and downslope no longer
differ between the two cases.
The drug treatments were then compared in time to evaluate if
the 0 min cases could be distinguished from the 10 min cases. The
Iso-1 0 min case was statistically distinguishable from the Iso-1
10 min case in all three parameters (width − = × −p value 2.2 10 4,
upslope − = × −p value 1.6 10 5, and downslope
− = × −p value 8.3 10 4). The Pro-1 0 min case was statistically dis-
tinguishable from the Pro-1 10 min case in width ( − = )p value 0.01
and upslope ( − = × )−p value 1.4 10 3 , but was not statistically
Fig. 5. DE analysis with respect to drug treatment for the lower SNR data. Iso-2
15 min (orange) and Control-2 (red) were different in width, but not in upslope or
downslope. (For interpretation of the references to color in this ﬁgure caption, the
reader is referred to the web version of this paper.)different in downslope ( − = )p value 0.28 .
In summary, KS-tests of DE widths, upslopes and downslopes
revealed that DEs immediately after isoproterenol administration
are distinguishable from controls. Similarly, DEs immediately after
propranolol administration are distinguishable from controls.
These differences are maintained 10 min after drug administra-
tion. DEs immediately after drug administration were also distinct
from DEs 10 min after drug administration, in both the iso-
proterenol and propranolol cases. Lastly, isoproterenol treated
cells were distinguishable from controls even at SNRs of 3 and
below. These results indicate that KS-test comparisons of DE
widths, upslopes, and downslopes, can accurately distinguish
drug-treated DEs from controls, even at low SNRs, and can also
distinguish drug-treated DEs based on the time after drug
administration.4. Discussion
4.1. Biological relevance
Development of next generation human cardiac in vitro pre-
clinical testing platforms is progressing at a rapid pace [4,9,20].
Non-invasive, high-throughput, automated electrophysiology
analysis methods that can provide data at the subcellular scale in
engineered 3D cardiac tissues are necessary to make these plat-
forms feasible as a rapid and reliable predictor of the cardiac side
effects of novel drugs under consideration for clinical trials. The
combination of using image-based electrophysiology (2-photon
microscopy of ﬂuorescent VSD) and advanced automated signal
processing (MaDEC) allows for the collection and quantitative
analysis of electrophysiological data on the spatio-temporal scale
needed in these advanced pre-clinical cardiac tissue models.
Furthermore, although the DEs presented here appear peri-
odically, the MaD algorithm takes a generalized approach to signal
detection. This allows for the detection of irregular DEs that may
be indicative of drug-induced side effects. Early afterdepolarization (EAD) and delayed after depolarization (DAD)
events are potentially lethal and may occur at irregular intervals
[6,28]. MaD does not incorporate the expected periodicity of car-
diac DEs into the detection algorithm, allowing for the ﬂexibility to
detect these types of events. In the event that periodic signals are
explicitly desired at low-SNR, the MaD detector could be modiﬁed
to apply a variable threshold to pick up low-SNR DEs at the ex-
pected time intervals, without increasing the number of FPs
throughout the entire dataset.
4.2. Effects of differing training samples
For some applications, it may be advantageous to reduce the
training samples size, in the interest of time. In our experience, the
noise sample is highly dependent on the length of individual noise
segments identiﬁed by the user. If long noise segments (more than
10 times the window size) are available, then as little as 10 seg-
ments can be sufﬁcient for accurate DE detection. Similarly, the
signal sample is dependent on SNR. If high SNR ( ≥ )SNR 5 DEs are
available for training, then as little as 10 samples are sufﬁcient for
accurate DE detection. However, if the signal SNR is lower, then at
least 20 samples should be used to maximize detection efﬁcacy.
Note that data pre-processing has little effect on SNR and serves
only to remove large scale artifacts produced by the motion of the
beating cell membrane and photobleaching of the VSD. Therefore
variations in pre-processing methods should not affect the training
paradigm.
It may also be useful to be able to re-use training samples be-
tween different data sets. To determine how re-using training
samples from one data set to detect DEs from a different data set
affects detection performance, we compared detection perfor-
mance when a native training sample (derived from the data being
tested) is used with detection performance when a non-native
training sample (derived from data of a different cell membrane
than the one being tested) is used. For this analysis we only tested
the Control-1, Iso-1, and Pro-1 detection cases, as the low-SNR
cases may not lead to reliable enough conclusions. All subsequent
results are presented at best performance as (TP% / FP%). Using a
non-native isoproterenol training sample on the Iso-1 data re-
sulted in ( )96.88%/4.62% using the full noise covariance and
( )99.22%/0.78% under the WGN assumption (ROC curves not shown
in the interest of space). Similarly, using a non-native propranolol
training sample on the Pro-1 data resulted in ( )90.48%/9.52% using
the full noise covariance and ( )100.00%/0.00% under the WGN as-
sumption. In the Control-1 case, using a non-native control
training sample resulted in ( )98.31%/1.69% using the full noise
covariance and ( )96.61%/1.72% under the WGN assumption. The
detector worked well even when Iso-1 training was used on Pro-1
data ( 85.71%/26.53% using full noise covariance; 100.00%/0.00%
under the WGN assumption) and vice versa (79.69%/28.67% using
full noise covariance; 98.44%/1.56% under the WGN assumption).
In all of these cases we see that detection performance is
maintained if a non-native training sample is used. Furthermore,
efﬁcacy is most often preserved under the WGN assumption.
When the full noise covariance is used with a non-native training
sample, detection performance may begin to degrade, indicating
that in the absence of a native noise covariance, the ﬁlter may
perform better using a WGN approximation than using a well
estimated but inaccurate, non-native noise covariance.
4.3. DE analysis
The automated MaDEC approach allows for quantitative com-
parison of DEs recorded from different drug treatments and time
points using VSDs. In this study, MaDEC was able to identify sig-
niﬁcant changes in DE width, upslope, and downslope
immediately after treatment with either propranolol or iso-
proterenol. These changes were sustained when measured 10 min
after exposure to each drug. Furthermore, MaDEC identiﬁed
changes in DE width between isoproterenol treated cells and
controls, even at SNRs of 3 and below. Propranolol and iso-
proterenol both act on β-adrenoreceptors in cardiac cells as a β-
blocker and β-adrenergic agonist, respectively. β-Adrenoreceptors
modulate calcium inﬂux during an action potential.
Calcium transport from the L-type calcium channels de-
termines the delay before repolarization. This delay determines
the width of the DE, also known as the plateau phase. The upslope
of a cardiac action potential, primarily driven by fast sodium
channels, would not be expected to be affected by β-adrenergic
modulation [17]. The downslope may be affected to a lesser degree
than the width since the balance of decreasing calcium channel
activity and increasing delayed rectiﬁer potassium channel (IKS, IKR,
and IK1) activity initiate the downslope.
Both isoproterenol- and propranolol-treated cell behavior,
quantiﬁed by MaDEC, exhibited signiﬁcant changes in width and
downslope after drug administration. However, the cells also de-
monstrated an unexpected difference in upslope after drug ad-
ministration. For the isoproterenol-treated cells, this difference
decreased with time ( − = × −p value 7.9 10 7 for Iso-1 0 min vs.
Control-1, and p-value¼0.02 for Iso-1 10 min vs. Control-1), and
seemed to be trending towards being insigniﬁcant. This indicates
that the difference in upslope may be due to an initial shock from
isoproterenol administration and that the effects may fade as the
tissue stabilizes. In contrast, the difference in upslope seemed to
increase in time for the propranolol-treated cells
( − = × −p value 2.5 10 3 for Pro-1 0 min vs. Control-1, and
− = × −p value 1.1 10 8 for Pro-1 10 min vs. Control-1). However,
both of the p-values are so close to zero, that they are difﬁcult to
reliably compare. When low-SNR isoproterenol-treated cell data
(Iso-2 15 min) was compared with a low-SNR control (Control-2),
only differences in DE widths were detected. Finally, we would like
to note that the DE widths of isoproterenol-treated cells increased
with respect to controls, in both low-SNR and high-SNR scenarios.
The mechanism of action of isoproterenol (β-adrenergic agonists)
would lead us to expect a decrease in the width of the DE. Despite
this unexpected, yet consistent, result, MaDEC still correctly
identiﬁed and quantiﬁed the effect of the drug, emphasizing its
impartial approach to DE detection and analysis.
4.4. Comparison with existing methods
VSDs address limitations of existing methods for measuring
hiPS-CM DEs. Patch clamping offers precise measurement of
transmembrane voltages, but is invasive in nature, requiring de-
structive membrane puncture to position electrodes that prevents
longitudinal experiments. Only single cells may be assessed using
a complex apparatus [2,13,26]. The growing ﬁeld of organ-on-a-
chip platforms demands non-invasive ﬂuorescence based in situ
endpoints for assessing hiPS-CMs [12,19]. VSD ﬂuorescence in-
tensity measurements using 2-photon microscopy are non-in-
vasive, non-destructive, and allow for longitudinal electro-
physiological assessment of live, 3D, cardiac tissues in micro-
ﬂuidic-based devices.
Quantitative assessment of the heterogeneity of the DEs of
actively beating cardiomyocytes is critical to understanding the
electrophysiology underlying these cardiac tissue models. Many
existing quantitative analysis tools studying cardiomyocyte activ-
ity were developed for calcium imaging applications. These are
often focused on automated region of interest (ROI) identiﬁcations
[22,3,1]. These image analysis tools are not readily applicable to
VSD imaging of cell membranes, where two-dimensional regions
of interest, are not necessarily spherical and are more difﬁcult toidentify. Algorithms focusing on line-scan data, and similar to the
MaD detector presented here, have been developed for Ca2þ spark
detection in cardiac ventricular myocytes [14], as well as ele-
mentary calcium release events in muscle [27]. However, these
algorithms focus only on detecting the signal and do not provide
further analysis tools for quantitatively assessing changes in tissue
or cell activity with varying experimental parameters (such as
drug administration). MaDEC can automatically and accurately
detect, extract, quantify, and compare VSD-based DEs across drug
treatments and time points after drug administration. Unlike other
VSD-approaches that use pre-deﬁned waveform features, MaDEC
uses a data-driven sample of the entire waveform to detect DEs,
resulting in a non-biased DE selection criterion that can accurately
detect waveforms at ≥SNRs 3. Also, unlike other approaches, DE
parameters such as width, upslope and downslope, are compared
across normalized waveform populations. The method's lack of
reliance on absolute ﬂuorescence amplitude ensures that results
are not biased by the amount of dye the cells took up, or the cells’
exact positions in the imaging plane.5. Conclusion
MaDEC is a useful new tool for the study of cardiomyocyte
electrophysiology. Combined with the use of voltage-sensitive
dyes, it allows for non-invasive, image-based, and automated
analysis of cardiac DEs. This study demonstrates the ability of this
tool to detect and quantify changes in DEs as a function of drug
treatment and as a function of time. The software is freely avail-
able at sites.uci.edu/aggies/downloads or from the corresponding
author, and can be easily modiﬁed to assess the electrophysiology
of other excitable cell populations (e.g. neurons) [23] and data
types (e.g. calcium reporters and patch clamp) [24].Conﬂict of interest
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